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Congenital hypogonadotropic hypogonadism/Kallmann syndrome (CHH/KS) is a rare,
treatable form of infertility. Like other rare disease patients, individuals with CHH/KS
frequently experience feelings of isolation, shame, and alienation. Unlike many rare
diseases, CHH/KS is not life threatening and effective treatments are available.
Nevertheless, it remains a profoundly life-altering condition with psychosocial distress
on a par with untreatable or life-limiting disease. Patients with CHH/KS frequently
express lasting adverse psychological, emotional, social, and psychosexual effects
resulting from disrupted puberty. They also frequently experience a “diagnostic
odyssey,” characterized by distressing and convoluted medical referral pathways,
lack-of-information, misinformation, and sometimes-incorrect diagnoses. Unnecessary
delays in diagnosis and treatment-initiation can significantly contribute to poor body
image and self-esteem. Such experiences can erode confidence and trust in medical
professionals as well as undermine long-term adherence to treatment–with negative
sequelae on health and wellbeing. This review provides a summary of the psychological
aspects of CHH/KS and outlines an approach to comprehensive care that spans medical
management as well as appropriate attention, care and referrals to peer-to-peer support
and mental health services to ameliorate the psychological aspects of CHH/KS.
Keywords: coping, hypogonadotropic hypogonadism, kallmann syndrome, patient activation, patient centered
care, patient experience, transitional care
INTRODUCTION
Congenital hypogonadotropic hypogonadism (CHH) is a rare genetic endocrine disorder causes by
the insufficient secretion or action of gonadotropin-releasing hormone (GnRH). Biochemically it is
defined by very low sex steroid levels (testosterone, estradiol) in the setting of low or inappropriately
normal serum levels of gonadotropins (luteinizing hormone, follicle stimulating hormone) (1).
Clinically, the condition manifests as absent or incomplete puberty with infertility. Thus, without
exogenous hormonal therapy, individuals remain in a state of arrested pubertal development.
Individuals typically exhibit some scant signs of androgenization (i.e., scant/Tanner II axillary and
pubic hair) arising from secretion of weak androgens by the adrenal glands. In males, the absence
of normal sex steroid levels is evidenced by lack of virilization, i.e., poor muscle development,
gynoid habitus, sparse body hair, high-pitched voice, and undeveloped genitalia. In females, there
are little to no secondary sexual characteristics (i.e., breast development, pubic hair) and absent
menses (amenorrhea).
Additionally, clinical presentation may be accompanied by a variety of highly variable non-
reproductive phenotypes (Box 1) (1, 2). Notably, when patients exhibit a diminished/altered
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Box 1 | Signs of CHH/KS and associated phenotypes.
Hallmark signs of absent/incomplete puberty
Males Females
• High-pitched voice • Absent/limited breast development
• No beard development
• Lack of muscle mass • Undeveloped feminine figure
• Scant body/pubic hair • Scant pubic hair
• Underdeveloped genitals • Primary amenorrhea
ASSOCIATED PHENOTYPES
Reproductive
• Maldescended testes (cryptorchidism)
• Micropenis
Sensory and Neurologic
• Defective sense of smell (hyposmia/anosmia)
• Sensorineural hearing loss
• Ocular and oculomotor defects (coloboma, micropthalmia)
• Mirror movement (synkinesia)
• Ataxia (Gordon-Holmes syndrome)
Musculo-Skeletal
• Eunuchoidal proportions
• Scoliosis, osteopenia/osteoporosis
• High arched palate
• Cleft lip/palate
• Dental agenesis
• Digit anomalies (syndactyly, clinodactyly, split hand-foot)
Dermatologic
• Pigmentation defects (achromic patches)
• Ichthyosis
Internal Organs
• Renal agenesis (unilateral)
• Heart defects
sense of smell (hyposmia/anosmia) it is termed Kallmann
syndrome (KS). Associated phenotypes occur at highly variable
rates. Thus, patients present on a spectrum ranging from
relativelymilder forms (e.g., CHHwith normal sense of smell and
partial puberty) to more severe, syndromic forms of CHH (e.g.,
Kallmann syndrome with complete absence of puberty, unilateral
renal agenesis and cleft lip/palate) (3).
THE CHALLENGE OF DIAGNOSIS
In parallel to the clinical heterogeneity of CHH, the molecular
basis is likewise diverse and complex (4). Inheritance patterns
include X-linked, autosomal recessive, autosomal dominant, as
well as digenic and oligogenic forms (5). Since the early 1990’s,
more than 30 genetic loci have been identified to underlie
CHH/KS. Significant advances have been made in understanding
the molecular basis of CHH/KS yet the known genes only
account for ∼50% of cases (1). As such, genetic testing may
be informative in helping to confirm a diagnosis in less than
half of cases, with the mainstay of diagnosis remains based
on clinical ascertainment and biochemical measurement of
serum hormones.
Importantly, CHH can be a difficult diagnosis to make.
The hallmark signs of CHH include failure to initiate
spontaneous puberty or inability to maintain progressive
pubertal development. In the general population, pubertal onset
Box 2 | Red flags pointing to CHH/KS diagnosis.
Positive family history—including offspring of CHH patients
secondary to fertility-inducing treatment
Signs of absent mini puberty (first 6-months of life)
◦ Maldescended testes (unilateral or bilateral cryptorchidism)
◦ Micropenis
◦ No erections noted during diaper changes
Absent sense of smell (anosmia)—typically not evident until age 6–8 years
Presence of midline or skeletal defects
◦ Cleft lip and/or palate
◦ Syndactyly (webbing) or other anomaly of digits
is highly variable. One may view a photograph of a middle school
class picture and quite easily see that some students have yet
to begin puberty (e.g., short stature and Tanner I) while other
classmates have begun or are well into puberty (e.g., growth spurt,
acne, facial hair development in boys and breast development in
girls). Indeed, delayed puberty statistically defined by the bell-
shaped curve of puberty (6). Constitutional delay of growth and
puberty (CDGP) occurs in 2.5% of the population and represents
those individuals at the far tail of the distribution who will
undergo spontaneous puberty—yet will do so significantly later
than their peers.
Currently, there is no gold-standard test to differentiate CDGP
from CHH. A number of serum biomarkers have been identified
and dynamic tests have been developed and evaluated. To date,
all these approaches lack appropriate sensitivity and specificity to
accurately tease apart delayed spontaneous puberty and abiding
absent puberty (7). In some cases, clinical “red flags” may point to
a diagnosis (1, 8–10) (Box 2). Unfortunately, such clinical signs
often go unrecognized (or their significance is not appreciated)
and a “watchful waiting” approach is taken (11). Making a
diagnosis is complicated and difficult because CHH/KS is a
diagnosis of exclusion and other potential causes (i.e., functional,
iatrogenic and tumors) must be ruled-out (1, 12).
Although a detailed three-generation family pedigree provides
important genetic insights to a case, it may not always
be informative for CHH/KS diagnostics. Studies demonstrate
that pedigrees of patients with CHH/KS are enriched with
family members with a history of delayed puberty (13, 14).
Thus, clinicians may incorrectly assume that the individual is
genetically programmed for late puberty. This can result in
a “watchful waiting” approach and a missed opportunity for
earlier diagnosis resulting from amore active investigation. Being
labeled a “late developer” or “late bloomer” may be difficult for
teens to accept and they may not feel healthcare professionals
are taking them seriously. Such feelings may further inhibit
patients discussing their puberty and seeking help for what may
be a highly sensitive and embarrassing condition. Guidelines and
review articles on delayed puberty are invariably directed at the
evaluation and treatment of individuals for whom the cause of
pubertal delay may not be initially obvious. However, a “watchful
waiting” lacks a logical basis for those individuals with “red flag”
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FIGURE 1 | Age at diagnosis. Left age at CHH/KS diagnosis for female patients (n = 55), median age at diagnosis = 18 years (mean: 21 ± 7 years). The gray shaded
region depicts the mean age of menarche plus two standard deviations (15). Figure adapted from Dzemaili et al. (16). Right age at CHH/KS diagnosis for male
patients (n = 101), median age at diagnosis = 18 years (mean: 18 ± 6 years, The gray shaded region depicts mean age of genital stage 3 plus two standard
deviations (17). Figure adapted from Dwyer et al. (18).
features (Box 2) indicating high pre-test probability of CHH/KS.
In such cases, sex hormone replacement therapy should not be
delayed beyond median age of pubertal onset. Cumulatively, all
these factors often contribute to a late diagnosis (Figure 1).
Moreover, patients with rare diseases often experience a
“diagnostic odyssey,” including incorrect diagnoses, incomplete
information, delays in finding expert care and accurate diagnosis,
and misleading or frankly incorrect advice along the way from
non-specialists. Such experiences can significantly erode patient
confidence in healthcare providers and health systems and affect
quality of life (19). For patients with CHH/KS, there is all
too often an unacceptable and inexplicable delay between the
age of presentation (e.g., at 3-months of age with bilateral
cryptorchidism and micropenis) and the age at diagnosis (e.g.,
at age 50 years with spontaneous vertebral fracture).
MISCONCEPTIONS REGARDING
TREATMENT
Unlike many rare diseases, there are simple, effective, affordable
treatments available for CHH/KS. Exogenous sex steroids can
safely and effectively induce development of secondary sexual
characteristics in males and females [reviewed in: (1, 20,
21)]. Similarly, exogenous gonadotropins (human chorionic
gonadotropin± recombinant FSH or pulsatile GnRH) can make
fertility possible in roughly 75–80% of male patients [reviewed
in: (1, 22–25)]. For female patients, ovulation induction can
be achieved using exogenous gonadotropins (FSH for follicle
development followed by hCG to induce ovulation) yet pulsatile
GnRH is the preferred treatment for fertility induction due
to decreased risk for multiples (26). If gonadotropins are
used for ovulation induction, the risk of multiples can be
mitigated by careful serial ultrasound monitoring to ensure that
only one single dominant follicle is ovulated following hCG
administration. Unfortunately, many patients are incorrectly
labeled as “sterile” and remain unaware that fertility is likely
possible with specialized regimens. For decades, using low
dose testosterone esters (in males) and low dose estradiol
(in females) has been the standard treatment to induce
secondary sexual characteristics. However, to date, there is no
standardized regimen to guide the induction of secondary sexual
characteristics, particularly in older adolescents or those of
adult age.
An important principle is starting with low dose replacement
and gradually escalating dosage in order to maximize growth and
attain normal breast contour in females. Importantly, females
started directly on full-dose estrogen and progesterone (i.e.,
hormone replacement therapy, combined oral contraceptive
pills) typically achieve markedly suboptimal breast development
(1). It remains unclear if optimal breast development results
from the progressive, incremental dose increase in estrogen, or
an indirect effect of delaying the introduction of progesterone
as long as possible. The classical approach is to introduce
progestin when girls begin to experience significant vaginal
spotting/bleeding on unopposed estrogen. Perhaps a more
logical approach might be to monitor endometrial thickness
by ultrasound to guide the adjustment of estrogen dose,
and thereby prolong the introduction of progesterone until
breast development is deemed appropriate. This point is
relevant because breast size and appearance can be a source
of significant anxiety and may impair body image for many
eugonadal women–let alone those women with CHH/KS.
Once cyclical estradiol and progesterone therapy has been
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initiated, some women will incorrectly presume that their regular
withdrawal bleeds will be associated with natural ovulation.
Hence, anticipatory guidance regarding fertility is important.
Additionally, monthly menses may be bothersome to many
women with CHH/KS—and potentially undermine adherence to
avoid menses. Patients should be informed they can safely have
a few withdrawal bleeds per year–rather than menses being a
monthly event.
In males, testosterone therapy will induce secondary sexual
characteristics, but will not stimulate testicular growth (either
gonadotropin therapy or pulsatile GnRH are required for this).
Patients are typically not informed of this fact. Accordingly,
male patients often have incorrect assumptions that testosterone
will induce puberty and normal appearing testes. Lack of
appropriate anticipatory guidance and patient education can
result in frustration and may erode a therapeutic relationship
between the patient and provider—and undermine adherence.
Further contributing to frustration and loss-of trust, reviews
and guidelines for pubertal-induction emphasize starting with
low-dose treatment aiming to complete pubertal maturation
over 2–3 years “in line with peer group.” For many patients,
this may seem agonizingly slow. For patients diagnosed at
an adult-age treatment regimen is both safe and appropriate
(27, 28). Once normal sex steroid levels in the serum have
been attained, lifelong treatment is required with at least
annual monitoring.
Recent studies have revealed that despite the presumed
availability of safe and effective treatment, there are major gaps
in both anticipatory guidance when initiating treatment as well
as significant challenges for long-term adherence to treatment
(16, 29, 30). Themajority of patients with CHH/KS are diagnosed
late (Figure 1) and thus, their physical appearance is much
younger than their chronological age. Patients have a strong
desire to “catch up” in pubertal development. Patients’ desire
to more closely resemble peers creates a temporal conflict with
the “slow and low” approach to dose increase. Patients may
become frustrated without appropriate anticipatory guidance
on when changes can be expected. Feelings of dissatisfaction
may undermine compliance with treatment (see Targets for
Improving Care). CHH/KS is a chronic condition and long-
term medication adherence is required for sexual function,
bone health, preventing potential metabolic disease and overall
well-being (1).
Like many chronic diseases, more than half of patients with
CHH/KS struggle with adherence and 48% of women and
38% of men have treatment gaps of more than 1 year (16,
29). Major drivers of adherence include patient beliefs and
concerns (31). While patients may be able to find clinicians
who are knowledgeable about CHH/KS, evidence suggests that
the understanding of the emotional and psychological aspects
of care are underappreciated and neglected. A quote from a
1964 article reflects this perspective: “There is a tendency among
physicians to assume that a corrigible pathological condition
ought to be corrected and that the emotional well-being of the
patient will improve concomitantly with his physical condition”
(32). The quote was published more than 50 years ago, yet
recent data suggest that this view persists. Sixty seven percent of
patients believe their provider understands the medical aspects of
CHH/KS. However, significantly fewer patients (38%, p < 0.001)
perceive their provider as understanding the emotional impact of
living with CHH/KS (30).
CHALLENGES FACED BY PATIENTS
Rare genetic diseases are often associated with psychological
burden and negative emotional and psychosocial effects (33).
Some have put forth the notion that challenges and inequities
faced by rare disease patients put them in the realm of health
disparities (34). Patients with CHH/KS may experience physical,
cognitive and psychosocial consequences (Box 3). The lack of
sex steroids due to CHH/KS can affect patients physically and
cognitively. Physically, sex steroids are critical for bone health—
both in formation and maintaining bone density. Because
patients with CHH are hypogonadal without treatment, periods
without treatment put them at increased risk for compromised
bone health (35, 36). Indeed, a Finnish study of 26 patients with
CHH found that long periods of non-adherence to treatment
Box 3 | Patient identified unmet needs*.
Knowledge of the CHH/KS
Patients often have limited understanding of the:
– Clinical difficulty in making a diagnosis
– Possibility of early (neonatal) identification
– Range and severity of signs and symptoms
– Symptoms that may or may not be associated
(e.g., fatigue, cognition/learning/attention problems—including autism
spectrum).
Access to Expert Care
Patients frequently have difficulty:
– Finding clinicians with experience in diagnosing CHH/KS
– Locating endocrinologists who know how to treat CHH/KS
(including fertility-inducing regimens)
Genetic Testing
Patients have a poor understanding of:
– The complex genetics of CHH/KS
– What can and can not be achieved through genetic testing
(i.e., treatment and potential risk of passing CHH/KS to offspring)
– How to communicate possible risk to family members
Treatment and Care
Patients are often unaware of:
– Types of physical/emotional changes that occur with treatment initiation
(including timing of changes and what will/will not occur on treatment)
– Necessity of long-term treatment
– Consequences of poor adherence on health and wellbeing
– Treatment options
(including dosage and timing intervals for testosterone injections)
Psychological and Psychosocial Consequences
Patients may not perceive:
– The importance of identifying and treating psychological issues related to
CHH/KS
(including those patients diagnosed early and those who are married with
children)
– The life-changing opportunities available through peer-to-peer support
(including body image concerns, self-esteem and sexuality)
*common concerns and issues raised by patients derived from online peer
discussions (personal communication–N. Smith).
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was associated with worse bone density (37). Thus, consistent
long-term adherence is essential for mitigating the risk for
osteopenia and osteoporosis.
In terms of cognition, sex steroids are known to have
activational and organizational effects on the brain and neural
circuits. Research findings indicate that periods of rising
circulating sex steroids (i.e., during the first 6-months of life in
the so-called “mini puberty” and during puberty) are important
developmental windows in which testosterone and estradiol have
sex-specific effects on brain and behavioral development (38).
While cognitive impairment is not a hallmark of CHH/KS and
most patients have normal IQ, there are data indicating lasting
effects on spatial abilities. A study comparing spatial abilities of
men with CHH and acquired HH found that deficits observed
in patients with CHH were not ameliorated by testosterone
treatment. These observations suggest that androgens exert a
permanent organizing influence on the brain (39). More recently
a study of 34 Lithuanian CHH males at diagnosis (prior to
sex steroid treatment) identified significantly lower executive
function, attention, visual scanning and psychomotor speed
compared to age-matched healthy controls (40). Notably, after 2
years of treatment, scored in these domains were improved—yet
without significant changes in either emotional state of quality
of life (41).
Approximately half to two-thirds of patients with CHH have
diminished/absent sense of smell (i.e., Kallmann syndrome) (1,
42). Patients with defective olfactory function may be prone to
eating food/drinks that have spoiled and often have concerns
about not being able to detect body odor- contributing to
feelings of self-consciousness and insecurity in social situations.
Similarly, studies of patients with isolated anosmia reveal
associations with increased social insecurity and depressive
symptoms (43). One’s olfactory acuity is indiscernible to others
but absent pubertal development and looking younger than
one’s age is outwardly evident. Indeed, the disparity between
chronological age and appearance can pose a significant barrier
for dating and intimate relationships. Puberty is a biologic
process that includes physiologic, psychosocial, and emotional
changes and adolescence is a period of developing self-concept.
Thus, disruption of puberty can carry a psychological burden (6).
Studies in late maturing 14–16 year-old boys identify body
image concerns, low self-esteem, social isolation and experiences
of teasing and bullying (44, 45)—common risks for depression
in adolescents (46). For patients with CHH/KS, experiences are
strikingly similar, if not magnified. Survey data indicate 56% of
females and 72% of males experience teasing and victimization
related to their condition. Body image concerns (e.g., body
shame) are reported in 93% of males and 80% of females with
CHH/KS. Supplementing these quantitative data, focus groups
discussions reveal that concerns about low self-esteem, shame
and social isolation are pervasive (16, 18, 30). These experiences
often have lasting effects and perhaps not surprisingly, significant
impact of intimate relationships and psychosexual development.
Prior studies of late maturing boys have revealed they are
more dissatisfied with their body image and less sexually active
compared to peers who underwent normal pubertal timing (47).
Studies in patients with CHH/KS corroborate these findings.
There are anecdotal reports in the literature mentioning
low self-esteem and poor body image among patients with
CHH/KS (32, 48, 49). Some have posited that pubertal failure
and underdeveloped genitalia (i.e., prepubertal testicular size
and small penis—both secondary to absent mini puberty)
may pose barriers to engaging in sexual activity (50). Online
patient discussions are filled with stories highlighting concerns
about genital development conveying the impact such concerns
have on seeking/initiating intimate sexual relationships. Studies
examining quality of life and sexuality in CHH have been sparse
with only a few small, anecdotal reports (32, 48, 49). More
recently, this topic has gained increased attention. Aydogan et al.
reported on 39 Turkish boys with CHH initiating testosterone
treatment. Prior to treatment, the youngmen exhibited increased
anxiety, depression, and worse quality of life (using the SF-36)
compared to age-matched controls (51). Notably, 6-months of
testosterone therapy improved physical function and vitality yet
increased anxiety and significant emotional difficulties persisted
as they adapted to life as a sexual adult (51). Longer duration
of treatment up to 2 years in a cohort of 19 Lithuanian boys
also failed to show significant improvements in emotional state
and quality of life (40, 41). A Finish study found decreased
quality of life in 30 males with CHH who exhibited high
levels of distress and depression (52). In 2014, Shiraishi et al.
studied six patients undergoing fertility-inducing gonadotropin
treatment over 2 years (53). In contrast to testosterone
replacement (51), gonadotropin therapy stimulates testicular
growth. The investigators observed significant improvement
in SF-36 measures including amelioration of the emotional
difficulties not seen with testosterone treatment. The authors
posited that the genital development might have had a role
in improving the emotional and body image concerns of the
six patients.
Subsequently, Dwyer et al. reported on the largest cohorts
studies to date (101 males, 55 females) providing robust
evidence of the psychosexual impact of CHH/KS pervasive (16,
18). Patients found intimate relationships as “very difficult”
(68% of males, 59% of females). Females were more likely
to have ever been sexually active (89%) compared to male
counterparts (74%). Notably, more than a quarter of men
with CHH have never been sexually active. This is five-
times the rate observed in similarly aged men drawn from
a population-based sample (26% vs. 5.4%, p < 0.001). In
parallel, qualitative focus groups explored the impact of disrupted
sexual maturation on psychosexual development and intimate
relationships in detail. Patients reported feeling isolated and
“left behind” as peers advanced through puberty and started
dating and taking on roles that are more adult. Fear and
anxiety about being exposed was common and many tried
to hide their lack of sexual development and sometimes
avoided social interactions—creating a reinforcing and cyclic
pattern that lasted well into adulthood (see Targets for
Improving Care) (18). Similarly, a Finnish study demonstrated
that despite long-term treatment, men with absent mini-
puberty (i.e., cryptorchidism with/without micropenis) had the
lowest scores on dimensions of sexual activity (52). These
data support the notion of persisting body shame and low
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FIGURE 2 | Targets for improving care and outcomes. Five main targets were identified from the literature and feedback from the patient community. Opportunities to
improve care and outcomes include: (1) better detection and earlier diagnosis, (2) activating and empowering patients for enhanced chronic disease
self-management, (3) promoting continuity of care through care coordination and structured transition from pediatric to adult-oriented care, (4) providing information,
enhanced mental health services and access to peer-to-peer support, (5) leveraging technology to extend the reach of care to geographically dispersed patients.
self-esteem despite long-term treatment with a lasting impact on
psychosexual functioning.
For patients with CHH/KS, the pervasive negative illness
perceptions provide insights into the burden many patients
face (16, 29). Notably, clinicians often underappreciate the
psychosocial impact of CHH/KS. Recent research indicates
that 34% of patients with CHH/KS exhibit moderate-severe
symptoms of depression (16, 29)—yet barely one quarter of
patients report ever having a provider discuss psychological
support or services. Patients with CHH/KS face a number of
challenges that range from feelings of isolation and alienation
related to living with a rare disease, possible physical and
cognitive issues as well as a constellation of emotional,
psychological, and psychosexual problems. It is worthwhile to
note that just as the clinical presentation and genetics of CHH/KS
are heterogeneous, so too are the coping responses of patients.
Some patients struggle with some or many of these challenges
yet others effectively cope with these difficulties. The following
section outlines areas for improving the care of CHH/KS and
avenues for supporting patient empowerment and more patient-
centered approaches to care.
TARGETS FOR IMPROVING CARE
As stated previously, CHH/KS is a difficult diagnosis to make. A
major challenge for clinicians and patients alike is the problem
of late diagnosis. Healthcare professionals can be frustrated by
the genetic heterogeneity of CHH/KS as well as the current lack
of plasma/serum biomarkers or sensitive and specific dynamic
test to differentiate CDGP and CHH/KS. For patients, the
psychosocial ramifications of late diagnosis can have lasting
effects. Thus, one of the main targets for improving care and
outcomes relates directly to enhanced detection and earlier
diagnosis (Figure 2). It is critical to raise clinician awareness of
red flags (Box 2). Defective sense of smell (anosmia) is a strong
clue for making a KS diagnosis. In male infants, signs of absent
mini puberty (e.g., cryptorchidism with/without micropenis)
during the neonatal window (first 6-months of life) represent the
earliest opportunity to make a diagnosis.
Other opportunities for improving the care and outcomes
for patients relate to chronic disease management. Patients
with CHH/KS must be activated and empowered for self-care.
Indeed, effective, long-term adherence to hormonal treatments
are critical for mitigating metabolic risks (e.g., metabolic
syndrome, type 2 diabetes) (54) and maintaining bone health
(37), sexual function, and well-being. Much has been written
on the topic of adherence and the subject is multifaceted and
complex yet adopting a patient-centered approach to care is
associated with better adherence. Briefly, the Picker Principles
of Patient-Centered Care (55) are integral parts of providing
high-quality healthcare and include: (1) respect for patients’
values, preferences and expressed needs, (2) coordination
and integration of care, (3) information, communication
and education, (4) physical comfort, (5) emotional support and
alleviation of fear and anxiety, (6) involvement of family and
friends, (7) continuity and transition, and (8) access to care. Thus,
effective patient-provider communication, therapeutic education
(including anticipatory guidance) and shared decision-making
are key elements for supporting adherence and patient self-
management. Patients with CHH/KS often have long gaps in care
(16, 30, 37). As with other chronic health conditions, continuity
of care is an important factor in reducing complications and
improving outcomes. Thus, co-ordinated care and structured
transition programs to effectively move young adults form
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Box 4 | Resources and links for patients.
Medical information and finding experts
https://rarediseases.info.nih.gov/diseases/10771/kallmann-syndrome
https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=478
https://www.chuv.ch/en/hhn/hhn-home/
Lay Information
https://www.youtube.com/watch?v=yKfThHq9Vjs
https://globalgenes.org/raredaily/the-24-year-old-late-bloomer-kallmann-
syndrome/
https://en.wikipedia.org/wiki/Kallmann_syndrome
https://www.chuv.ch/en/hhn/hhn-home/
Patient Perspectives and Peer-to-Peer Support
Facebook:
– Kallmann Syndrome Links and Help (OPEN group)
– Kallmann Syndromers (CLOSED group)
– Kallmann Syndrome & Hypogonadotropic Hypogonadism (SECRET group)
https://www.news-medical.net/health/Kallmann-Syndrome.aspx
https://www.rareconnect.org/en/community/kallmann-syndrome
https://www.youtube.com/watch?v=eitQYgCqA-0
General Rare Disease Resources
https://rarediseases.org/
https://www.eurordis.org/
http://www.agsa-geneticsupport.org.au/
*Working links as of August 2018.
pediatric to adult-oriented care are critical for closing gaps in
care (56, 57).
Patients frequently express the desire for more information
(16, 30) (Boxes 3, 4). Importantly, healthcare professionals and
patients have complementary knowledge and expertise. Providers
understand the genetics, pathophysiology and treatment while
patients understand what it is like to live with a rare disease.
This presents opportunities for co-creating solutions—as recently
demonstrated in a project pairing expert clinicians and patients
to create patient educational materials in lay language (and
translated into 20 languages) (58). Moreover, peer-to-peer
support is ameans to pierce the veil of isolationmany patients feel
and offer opportunities for patients to connect and crowdsource
solutions (30). There is a need to raise provider sensitivity to
the psychosocial aspects of CHH/KS to increase screening for
symptoms of anxiety and depression. Further, many patients may
benefit from mental health services to address self-esteem and
psychosexual issues.
Rare disease patients are dispersed geographically. This makes
is difficult for patients to reach expert centers and clinicians
who are experienced in using specialized fertility-inducing
regimens. Therefore, leveraging technology to reach dispersed
patients and connecting patients with specialists is a key part
of improving care for CHH/KS. As demonstrated in a recent
needs assessment (30), patient partnerships combined with a
web-based approach is a highly effective. Patients with rare
diseases are internet “power-users” who go online to learn
about their condition, access care, and connect with other
patients (59). An international network of CHH/KS clinicians
and researchers partnered with patients and advocates to respond
to the unmet needs identified in the needs assessment. Together,
they collaboratively developed a virtual toolkit to help patients
learn about their condition, find clinical centers, access genetic
testing services and join peer-to-peer support groups (58). This
example highlights how respectful and trusting patient-provider
partnerships can use co-creation to translate research into
improved clinical care. Importantly, for long-term sustainability
of such platforms, ongoing patient engagement and participation
will be essential.
FUTURE DIRECTIONS
There are a number of unanswered questions related to CHH/KS.
Studying rare diseases and developing an evidence base to
guide best practices is challenging as publications typically
come from single centers and have relatively small populations.
One opportunity is for broader, international collaboration
with harmonized definitions and measures. Patient registries
are particularly helpful for rare disease research (60). Such
tools can be used to conduct natural history studies and
better understand long-term health outcomes and impact on
quality of life.
For CHH/KS, such a natural history study could be extremely
useful for exploring the phenomenon of reversible CHH (61).
Data suggest that ∼10% of patients recover function of their
hypothalamic-pituitary-gonadal axis and can sustain normal sex
steroid levels and fertility following discontinuation of hormonal
treatment (62). Interestingly, reversal is not always lasting and
these patients appear susceptible to relapse and a subsequent
“crash” of their reproductive axis (63). Long-term studies of such
cases could potentially help identify biomarkers and predictors
for reversal and potentially open new avenues for developing
novel treatments. Registries and natural history studies can also
help examine how CHH/KS evolves over time and the impact
on quality of life. These data can be used to identify patient-
reported outcome measures (PROMs) (64, 65). Subsequently,
identified PROMs could be used as outcomes and secondary
endpoints for clinical trials (66). Indeed, further work is needed
to clarify the optimal treatment(s) for CHH/KS and the best
timing for treatment initiation (1). Thus, a patient registry and
natural history study could help advance the field.
Additional future directions include developing tools and
identifying biomarkers to facilitate early diagnosis. Genetic
testing can be informative in approximately half of cases.
However, an unmet need is access to decisional support for
genetic testing. Online discussions and unpublished data indicate
that patients may struggle with genetic testing decisions—
particularly related to the complex genetics of CHH/KS (5).
Patients could benefit from decisional support, interventions
promoting active coping strategies and approaches supporting
effective family communication of risk. Currently, expertise in
specialized fertility-inducing treatment is limited and dispersed.
Future directions may include international multicenter trials to
determine optimal treatment regimens and using web-based “e-
consulting” to share this dispersed, specialized expertise. More
work is needed to develop and test effective both face-to-face and
web-based interventions for activating and empowering patients
for long-term adherence and self-management. Additionally,
transitional care has only recently gained attention. As such,
there is a limited evidence base for supporting best practices
(or exemplar models) for effectively transitioning patients from
pediatric to adult oriented care.
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CONCLUSIONS
Congenital hypogonadotropic hypogonadism and Kallmann
syndrome (CHH/KS) is a rare, treatable form of infertility.
Like other rare disease patients, individuals with CHH/KS
frequently experience feelings of isolation and alienation.
Effective hormonal treatments are readily available for inducing
secondary sexual characteristics and fertility (in the vast majority
of cases). Indeed, CHH/KS is not life threatening, but it is
a severely life-altering condition. Disrupted puberty can have
lasting psychological, emotional, and sexual effects. As part of
comprehensive care, clinicians should give appropriate attention,
care and referrals (e.g., peer-to-peer support, mental health
services) as appropriate to ameliorate the psychological aspects
of CHH/KS.
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